Yuntao Shi1,2, Zhonghong Wang3, Xiaojuan Zhu1, Ling Chen1, Yilan Ma1, Jiayan Wang1, Xiaozhong Yang4, Zheng Liu5. 1. Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, No.121, Jiangjiayuan Road, Nanjing, 210011, China. 2. Department of Gastroenterology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, No.1, Huanghe West Road, Huaian, 223300, China. 3. Department of Gastroenterology, Huaian People's Hospital of Hongze District, Huaian, 223100, China. 4. Department of Gastroenterology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, No.1, Huanghe West Road, Huaian, 223300, China. xz_yang1023@aliyun.com. 5. Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, No.121, Jiangjiayuan Road, Nanjing, 210011, China. liuzhenghjk@163.com.
Abstract
BACKGROUND: Gastric cancer (GC) patients are usually diagnosed in advanced stages which results in high mortality. This study aimed to identify novel circulating miRNAs as biomarkers for the early detection of GC. METHODS: Candidate miRNA was identified after integrated analysis of two Gene Expression Omnibus (GEO) datasets and clinical serum samples. Exosomes extracted were verified using transmission electron microscopy (TEM) and western blot. The expressions of miRNAs were tested through qRT-PCR. Receiver operating characteristic curve (ROC) analysis was used to explore the diagnostic utility of miRNAs. RNA pull-down assay was used to find RNA binding proteins (RBPs) which transport candidate miRNA into exosomes. Bioinformatics analysis of candidate miRNA was conducted using DAVID and Cytoscape. RESULTS: After integrated analysis of two GEO datasets, six circulating miRNAs were found to be consistently upregulated in GC patients. Then, qRT-PCR demonstrated that serum miR-1246 was the one with the largest fold change. Studies in vitro revealed that elevated serum miR-1246 was tumor-derived by being packaged into exosomes with the help of ELAVL1. Thereafter, we discovered that exosomal miR-1246 expressions in serum could differentiate GC patients with TNM stage I from healthy controls (HCs) and patients with benign diseases (BDs) with area under the curve (AUC) of 0.843 and 0.811, respectively. Bioinformatics analysis revealed miR-1246, as a tumor suppressor in GC, could regulate several signaling pathways. CONCLUSION: Circulating exosomal miR-1246 was a potential biomarker for the early diagnosis of GC.
BACKGROUND:Gastric cancer (GC) patients are usually diagnosed in advanced stages which results in high mortality. This study aimed to identify novel circulating miRNAs as biomarkers for the early detection of GC. METHODS: Candidate miRNA was identified after integrated analysis of two Gene Expression Omnibus (GEO) datasets and clinical serum samples. Exosomes extracted were verified using transmission electron microscopy (TEM) and western blot. The expressions of miRNAs were tested through qRT-PCR. Receiver operating characteristic curve (ROC) analysis was used to explore the diagnostic utility of miRNAs. RNA pull-down assay was used to find RNA binding proteins (RBPs) which transport candidate miRNA into exosomes. Bioinformatics analysis of candidate miRNA was conducted using DAVID and Cytoscape. RESULTS: After integrated analysis of two GEO datasets, six circulating miRNAs were found to be consistently upregulated in GC patients. Then, qRT-PCR demonstrated that serum miR-1246 was the one with the largest fold change. Studies in vitro revealed that elevated serum miR-1246 was tumor-derived by being packaged into exosomes with the help of ELAVL1. Thereafter, we discovered that exosomal miR-1246 expressions in serum could differentiate GC patients with TNM stage I from healthy controls (HCs) and patients with benign diseases (BDs) with area under the curve (AUC) of 0.843 and 0.811, respectively. Bioinformatics analysis revealed miR-1246, as a tumor suppressor in GC, could regulate several signaling pathways. CONCLUSION: Circulating exosomal miR-1246 was a potential biomarker for the early diagnosis of GC.
Authors: Damian Szklarczyk; Andrea Franceschini; Stefan Wyder; Kristoffer Forslund; Davide Heller; Jaime Huerta-Cepas; Milan Simonovic; Alexander Roth; Alberto Santos; Kalliopi P Tsafou; Michael Kuhn; Peer Bork; Lars J Jensen; Christian von Mering Journal: Nucleic Acids Res Date: 2014-10-28 Impact factor: 16.971
Authors: Wen Cai Zhang; Tan Min Chin; Henry Yang; Min En Nga; Declan Patrick Lunny; Edwin Kok Hao Lim; Li Li Sun; Yin Huei Pang; Yi Ning Leow; Shanneen Rossellini Y Malusay; Priscilla Xin Hui Lim; Jeravan Zili Lee; Benedict Jian Wei Tan; Ng Shyh-Chang; Elaine Hsuen Lim; Wan Teck Lim; Daniel Shao Weng Tan; Eng Huat Tan; Bee Choo Tai; Ross Andrew Soo; Wai Leong Tam; Bing Lim Journal: Nat Commun Date: 2016-06-21 Impact factor: 14.919
Authors: N Takeshita; I Hoshino; M Mori; Y Akutsu; N Hanari; Y Yoneyama; N Ikeda; Y Isozaki; T Maruyama; N Akanuma; A Komatsu; M Jitsukawa; H Matsubara Journal: Br J Cancer Date: 2013-01-29 Impact factor: 7.640
Authors: Farzaneh Moshiri; Alessandro Salvi; Laura Gramantieri; Angelo Sangiovanni; Paola Guerriero; Giuseppina De Petro; Cristian Bassi; Laura Lupini; Arash Sattari; Douglas Cheung; Dario Veneziano; Giovanni Nigita; Ram C Shankaraiah; Nazario Portolani; Paolo Carcoforo; Francesca Fornari; Luigi Bolondi; Antonio Frassoldati; Silvia Sabbioni; Massimo Colombo; Carlo M Croce; Massimo Negrini Journal: Oncotarget Date: 2018-02-27